GLP-1s are quickly reshaping the Australian prescription medicines market

Should industry groups present the agreement negotiations to patient groups and 'invited' stakeholders, and if so, what should they say? Why the private market for GLP-1 medicines could be a historic catalyst for the changes so many want.

As the review process approaches its end, like a drunk stumbling home from a big night out, a dynamic, people-focused private market has emerged for GLP-1 medicines for weight loss. Australians have responded.

US PhRMA, the country's equivalent of Medicines Australia, has taken the Trump administration to court over a Medicare rule that ties what the United States pays for some medicines to the prices paid in 19 other wealthy countries, including Australia.

Signatories include AusBiotech, Medicines Australia, the Medical Technology Association of Australia, the Australian Academy of Science, Research Australia and Science and Technology Australia.

Australia's peak body for the biotechnology sector has used its 40th anniversary to warn that Australia's attractiveness as a base for the sector is not permanent, as rival nations sharpen incentives and compete harder for the industry.

Moderna and Australia's national science agency CSIRO have struck a five-year research collaboration to strengthen the nation's biosecurity capability and pandemic preparedness, with a potential human vaccine against Hendra virus selected as the first project under the new partnership.

An Australian company has taken one of the country's top design honours for a machine built to solve one of healthcare's most stubborn cleaning problems.

Experience over the past two decades shows that reform without legislating changes to Section 101(3B) that loosen the comparison requirement or impose new obligations on the committee, specifically regarding patients, would produce minimal change.

The first sentence treats someone seeking a particular treatment as a problem. The second says that the person should help make the decision. The TGA cannot have it both ways.

New Zealand medicine maker AFT Pharmaceuticals says it remains on track to hit its NZ$300 million revenue target for the 2027 financial year after every division posted double-digit revenue growth in the first half.

The TGA is using an artificial intelligence-enabled surveillance platform rooted in national security and counter-terrorism work to support compliance activities, including policing advertising for therapeutic goods.

The impact of new media guidance from Australia's health technology regulator can now be assessed against the backdrop of its use of an AI platform initially developed for, and still used by, intelligence and law enforcement agencies. Why is the debate in Australia so limited, confined to a small group of privileged insiders, and why do so many appear uncomfortable with patients having meaningful rights?

Average pay for chief executives of Australia's largest listed health care and biotechnology companies rose for a second consecutive year in 2026, while average pay at the smallest companies fell, according to a new benchmarking report.

CSL has agreed to pay Alentis Therapeutics US$355 million upfront in an exclusive deal to jointly develop and promote lixudebart, an experimental antibody that could become the first in a new class of treatments for people with rare kidney and liver diseases.

More young New Zealanders with cancers that usually strike in childhood will soon be able to get funded treatment, after Pharmac changed a long-standing rule that tied access to the ward where a patient was treated.

Australians living with wet age-related macular degeneration may soon be able to replace regular eye injections with a refillable implant that continuously releases medication.

The guidance flags content that "presents personal experiences, testimonials, endorsements or expert commentary in a way that encourages consumers to use or seek out a product". A patient who describes how a medicine changed their life is sharing a statement that reflects their lived experience, and it deserves unconditional respect.

Prices paid for medicines in Australia, Japan, the United Kingdom and 16 other countries will now help set what US-based companies owe a major US government prescription medicine program.

Generic and biosimilar maker Sandoz heads 'Great Place To Work' Australia's first list of the best workplaces in biotechnology and pharmaceuticals for 2026.

In this publication's 14 years, only one organisation has answered questions with responses that its internal documents subsequently revealed reflected a decision to mislead. The TGA has been the only one, and the question concerned advertising. That same agency judges what counts as genuine news and the public interest.